Breast Cancer Recurrence – the Accuracy of Dual-time PET/CT

Overview

The purpose of this study is to elucidate the value of dual-time-point PET/CT in the recurrence of breast cancer and to determine whether the method is better than the modalities used in the standard work up. 150 patients with suspected breast cancer recurrence will be included. All patients will undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After completion of the examinations the early and the late PET/CT scan will be compared with each other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained, the presence of recurrence will be verified with additional imaging follow-up to ensure the highest possible confidence. Sensitivity, specificity, accuracy, negative and positive predictive value (NPV/PPV) will be calculated for each modality (incl. early and late PET/CT).

Full Title of Study: “Breast Cancer Recurrence – the Accuracy of Dual-time PET/CT”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Investigator)
  • Study Primary Completion Date: December 2014

Interventions

  • Radiation: Dual-time PET/CT (low-dose)
    • 4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.

Arms, Groups and Cohorts

  • Other: Dual-time PET/CT

Clinical Trial Outcome Measures

Primary Measures

  • Diagnostic value of dual-time point 18FDG PET/CT in recurrent breast cancer
    • Time Frame: 2 years
    • The sensitivity and specificity of dual-time point 18FDG PET/CT will be compared to conventional imaging modalities usually used in the work up of patients with suspected recurrent breast cancer. In this case CT of thorax and upper abdomen and bone scintigraphy.

Secondary Measures

  • Diagnostic value of early and late 18FDG PET/CT respectively in recurrent breast cancer
    • Time Frame: 2 years
    • The sensitivity and specificity of early (60 min post injection) and late (180 min post injection) 18FDG PET/CT respectively in patients with suspected recurrent breast cancer.

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical suspected recurrence of breast cancer – Blood glucose level less than 8,0 mmol/L Exclusion Criteria:

  • Disqualified patients – Other malignancies – < 18 years – < 50 kg – > 90 kg – Pregnant or lactating – Patients with permanent address outside of the Region of Southern Denmark – Estimated inability to collaborate

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Odense University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kirsten Falch, Medical Technologist – Odense University Hospital
  • Overall Official(s)
    • Malene Hildebrandt, M.D., Principal Investigator, Dept. Nuclear Medicine, Odense University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.